One Biosciences announces the appointment of Hedi Ben Brahim as Chief Executive Officer
07 Septiembre 2023 - 6:30AM
One Biosciences, a biotech leveraging the power of single-cell
analysis and AI to unlock a new wave of targets and precision
medicines for a broad range of difficult-to-treat diseases, today
announced the appointment of Mr. Hedi Ben Brahim as its Chief
Executive Officer (CEO). Hedi is a recognized leader in the
biotechnology industry, joining from Transgene (Euronext: TNG)
where he served as Chief Executive Officer.
Mr. Ben Brahim was appointed CEO as part of a
planned process in order to maximize the potential of the Company’s
discovery engine and push its first assets towards pre-clinical
development. His appointment is in line with Home Biosciences’
venture builder business model and majority shareholder position
and serves as foundation for One Biosciences’ forthcoming series A
financing. He replaces Mrs. Magali Richard, who has served as CEO
of One Biosciences, being co-founder of the Company and deputy CEO
of Home Biosciences. She will transition to Chief Operating Officer
(COO) of One Biosciences, supporting Hedi in his onboarding.
David Schilansky, CEO of Home
Biosciences, Chairman of the Board of Directors of One
Biosciences, said: “We are extremely happy to welcome Hedi
Ben Brahim, a recognized leader in our industry, who has
successfully led innovating products into clinical development, at
such an exciting time for One Biosciences. We look forward to
maximizing the value of its discovery engine as we gear up for a
Series A financing.”
Hedi Ben Brahim, One Biosciences’ new
Chief Executive Officer, said: “After having left a
well-established, listed biotech, I took the unmissable opportunity
to lead an entrepreneurial project. I am thrilled to join One
Biosciences at such a pivotal moment, as the company seeks to
advance its first targets into drug development and raise funds for
its scale up. One Biosciences has all the key ingredients for a
landmark success: impressive science based on a revolution in
biology, a strong technological edge, professional and highly
skilled teams, a strong link with Institut Curie, and outstanding
results stemming out of its discovery engine.”
Magali Richard, deputy CEO of Home
Biosciences, COO and co-founder of One Biosciences said:
“Home Biosciences is fulfilling its role of company builder,
guiding innovations through each step from discovery to life
changing therapies for patients. One Biosciences’ progress
demonstrates why Home Biosciences is the partner of choice for
scientists to create, build, and grow sustainable ventures.
Transitioning to a full-time CEO is another critical step achieved
and Hedi’s exceptional track record will be invaluable as One
Biosciences moves into its next stages of growth.”
Hedi Ben Brahim was CEO of Transgene from 2021
to 2023. During his tenure, he and his team launched two products
in clinic and demonstrated the unique benefits of viral based
personalized vaccines in a promising phase 1 trial. Prior to that,
Hedi was Vice-President, Immunotherapy of Institut Mérieux from
2018 to 2020. In this role, he was the Chairman of ABL Inc., a
contract research & development, and contract biomanufacturing
organization (CRO/CMO). Prior to joining the Institut Mérieux, he
was General Manager at a subsidiary of Vallourec, a solutions
provider to the energy sector. Hedi began his career in the public
sector at the Ministry of the Economy, Action and Public Accounts,
then at the Ministry of Social Affairs and Health. He is a graduate
of École Polytechnique and École Nationale Supérieure des Mines de
Paris.
About One Biosciences
One Biosciences leverages the power of
single-cell analysis and AI to unlock a new wave of targets and
precision medicines for a broad range of difficult-to-treat
conditions. One Biosciences is an integrated discovery engine
combining a multi-disciplinary team with in-house computational
capabilities. One Biosciences is backed by Institut Curie and Home
Biosciences. For more information, visit: www.onebiosciences.fr
Contact
contact@onebiosciences.fr
US press
McCargo Mission-Aligned CommunicationsJanine
McCargojanine@mmac.me
Transgene (EU:TNG)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Transgene (EU:TNG)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024